On-the-go consumers are turning to healthy snacks to satisfy their cravings for taste, functionality and
convenience, as better-for-you snack brands capitalize on interest in GLP1 drugs by introducing products
that promote satiety and address different need states. The topic of healthy snacks will be the focus of
FoodNavigator-USA’s upcoming editorial webinar.
Moderated by FoodNavigator-USA Senior Correspondent Ryan Daily, “Elevating healthy snacking: Meeting demand for function, flavor,
format” on July 10 at 11 am CT will feature a panel discussion on how brands are responding to demands for healthier and more
nutritious products through innovation.
The webinar’s panel will feature snack brand founders, innovators, market analysts and investors in the better-for-you snack space,
including:
- Sherry Frey, VP of total wellness at NielsenIQ
- Marc Washington, founder and CEO of Supergut
- Peter Barrick, CEO of Rivalz
- Samil Ozavar, SVP of strategy and innovation for Cibo Vita
- Melissa Dolan, director for Emil Capital Partners
GLP1 drugs elevate the health discourse in the US
Frey will open the webinar exploring macro trends that are influencing the snack segment, sharing insight from NielsenIQ’s
Snackonomics survey that shows how better-for-you snacks are driving market growth as consumers demand products that satisfy
their taste buds, nutrient needs and budgets.
Recently, Frey presented at the Food as Medicine event in Chicago, where she discussed how the emergence of GLP1 drugs like
Ozempic and WeGovy have shifted the conversation around obesity and health in the US.
GLP1 drugs have been touted as a possible solution to the obesity and diabetes epidemics in the US. Advocates of GLP1 drugs say
they can help consumers lose weight by sharply reducing appetite, while opponents of the drugs question their price and raise
concerns about side effects.
In a recent survey of more than 1,400 consumers, the Kaiser Family Foundation found that 12% of consumers said they tried a GLP1
drug, and 6% said that they are currently on a GLP1 drug. Additionally, 62% of consumers said they are taking the drug to address a
chronic condition, including diabetes or heart disease, and approximately 40% said they are taking GLP1 drugs to lose weight.
Better-for-you snack respond to the GLP1 effect
Large CPG companies like Nestlé are following the GLP1 trend. The CPG giant recently launched a Lean Cuisine line of frozen meals for
those on GLP1 drugs. Snack brands are also leaning into the demand for GLP1 benefits and releasing products that mirror some of the
drugs’ benefits.
With its portfolio of snack bars and powders, Supergut found success in the market — recently launching in GNC stores nationwide as
part of its GLP1 section — by serving as a complement to treatment plans and an off-ramp for Ozempic and WeGovy.
Additionally, salty snack brand Rivalz is tapping into the demand for products to deliver fullness with its portfolio of products that
promote satiety through protein- and fiber-rich snacks, which are made possible through its patented extrusion technology.
During the webinar, Washington and Barrick will share how the GLP1 trend has evolved, and how consumers are looking for products
that promote satiety and gut health. Ozavar will also share how Cibo Vita is capitalizing on the demand for probiotic-rich foods with its
Probiotic Yoggies fruit bites, created with the company’s encapsulation technology.
How brands are navigating the capital crunch?
While better-for-you snacks are capitalizing on interest in gut health and GLP1, food and beverage startups are facing the challenge of
ensuring they have enough capital to grow their business, amid high interest rates and low levels of venture-capital funding.
Supergut made a series of cuts to streamline its business and grow into GNC stores, as the brand enters fundraising mode to fuel
further growth, Washington previously shared.
At Expo West, Dolan shared her perspective on the state of venture-capital funding, noting brands that survive the next year should see
better investment prospects.
“There has been a lot of doom and gloom over the last 12 months, [and] it is a really challenging fundraising environment. I think the
good news is consumer products are not going anywhere, and … we will come into a time — and I am willing to bet it is in the next two
to three years — where strategics — [large CPG companies] — are looking to snatch up relevant brands again. So, buckle down, make it
through this year, and there is massive light at the end of the tunnel,” Dolan
